Research programme: antibody-toxin conjugates - VasGene Therapeutics
Alternative Names: Vas 201; Vas 202Latest Information Update: 28 Feb 2020
At a glance
- Originator VasGene Therapeutics
- Class Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in USA
- 22 Jan 2016 Early research in Cancer in USA (unspecified route) before January 2016